While Artificial Intelligence (AI) has emerged as groundbreaking and significantly impacting various sectors and enhancing quality of life, the chasm between technological advancements and the law is ...

For decades, artificial intelligence advanced in careful, mostly linear steps. Researchers built models. Engineers improved performance. Organizations deployed systems to automate specific tasks. Each ...

Another day, another announcement about AI agents. Hailed by various market research reports as the big tech trend in 2025 — especially in the enterprise — it seems we can't go more than 12 hours or ...

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

In my recent interview, Satya Nitta, co-founder and CEO of Emergence AI, described a future where artificial intelligence doesn’t just assist—it creates. The New York-based startup, backed by $100 ...

We recently published a list of the 13 Best Artificial Intelligence Stocks Under $50 to Buy Now. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ...

Recursion Pharmaceuticals (RXRX +4.77%) is not the most famous artificial intelligence (AI) stock on the market, but the biotech (or techbio) company has attracted the attention of some big names.

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...